肺动脉高压的治疗PPT资料.ppt
《肺动脉高压的治疗PPT资料.ppt》由会员分享,可在线阅读,更多相关《肺动脉高压的治疗PPT资料.ppt(25页珍藏版)》请在冰豆网上搜索。
![肺动脉高压的治疗PPT资料.ppt](https://file1.bdocx.com/fileroot1/2022-10/8/3efcaafd-8d4c-462e-8291-3260c0b5ffca/3efcaafd-8d4c-462e-8291-3260c0b5ffca1.gif)
334:
296前列环素-持续静脉内滴注(依前列醇Epoprostenol,Flolan)依前列醇-持续静脉内滴注(Epoprostenol)硬皮病引起的肺动脉高压Badesch(PHTinSclerodermaSpectrumofDiseaseStudyGroup)randomized,controlledtrial,17centers,111patientsimprovedexercisecapacity(6mwalk),NYHAclassanddyspeascores.mPAP,PVRAnnInternMed.2000;
132:
425曲前列环素-持续皮下输注(Treprostinil(Remodulin),UT-15)chemicalstable,longerhalf-life12week,double-blind,randomized,placebo-controlled,andmulticentertrialin470PAHpatientsImprovedexercisecapacity,indicesofdyspnea,signsandsymptomsinPAHSimonneau(European,USA).AmJRespirCritCareMed.2002;
165:
800结缔组织疾病伴PAHOuidz2004静脉应用转换至皮下Vachiery2002贝前列环素-口服(Beraprost,Dorner)ArterialPulmonaryHypertensionandBeraprostEuropeanTrial(ALPHABET)StudyGrouparandomized,double-blind,placebo-controlledtrial.130PAHpatientsimproveexercisecapacityandsymptomsGalie.2002Barst2003与西地那非合并应用Ikeda2005疗效差于epoprotenolBerman2004伊洛前列素(万他维)-吸入Iloprost(Ventavis)TheAerosolizedIloprostRandomizedStudyGroupseverepulmonaryhypertensionlarge(203),placebo-controlledtrialwalkdistance,hemodynamic,NYHAclass,qualityoflifeOlschewski.2002HIV-relatedPAHGhofrani2004妊娠伴妊娠伴PAHElliot2005内皮素受体拮抗剂Endothelin-1potentendogenousvasoconstrictor,smoothmusclemitogenoverexpressedinplasmaandlungtissueofpatientswithPPHandsclerodermamediatedbytworeceptors,ETAandETBActivationofbothETAandETBonSMCleadstovasoconstrictionActivationofETBonendothelialcellsleadstovasodilationFagan2001波生坦,Bosentan(Tracleer)oralantagonistofbothendothelinreceptorsPulmonaryArterialHypertension(PAH)Improvesexercisecapacity,Borgdyspnea,andWHOclass,ReducedclinicalworseningChannickRN.Lancet.2001;
358:
1119RubinLJ.NEnglJMed2002;
346:
896SitbonO.2003McLaughlin2005SystemicSclerosisassociatedwithPAHHumbertM.2003门脉高压患者合并PAHHoeper2005SelectiveETAreceptorAntagonists西地生坦(Sitaxsentan)BarstRJ.Chest.2002;
121:
1860BarstRJ.2004Langleben2004安贝生坦(Ambrisentan)Galie2005治疗:
一氧化氮(NO)一氧化氮(nitricoxide,NO)synthesizedfromL-arginineandO2byNOsynthase(NOS),activatesGC,increasecGMPmaintainnormallowpulmonaryvasculartone,opposeincreasesintonecausedbyhypoxiaorothervasoconstrictors.levelofexhaledNOisreducedinpatientswithPPHCremona,QJM1994;
87:
547一氧化氮吸入-急性血管舒张试验:
-Sitbon.AmJRespirCritCareMed.1995;
151:
384原发性肺动脉高压:
德国原发性肺动脉高压研究协作组CardiacOutput(CO),PAP,PVR.Hoeper.JAmCollCardiol.2000;
35:
176“桥”肺移植Snell.AmJRespirCritCareMed.1995;
1263AmbulatorydeliverysystemChannick.AmJRespirCritCareMed.1994;
1482一氧化氮吸入
(2)慢性阻塞性肺疾病(COPD):
单纯吸入NO:
PAP,PVR,SAPAdnot.AmRevRespirDis1993;
148:
310Moinard.AmJRespirCritCareMed1994;
149:
1482Vizza.CritCare2001;
5:
355Ashutosh.Thorax2000;
55:
109Kanniess.RespirMed2001;
95:
927GOLD(WHO/NHLBI)推荐应用长期氧疗(LTOT):
增加运动耐量,延长患者寿命吸入NO+LTOT:
mPAP,PVRGermannChest.1998;
114:
29PaO2?
PaCO2?
CO?
5型磷酸二酯酶抑制剂西地那非(伟哥)(Sidenafil,Viagra):
磷酸二酯酶(PDE)-5抑制剂NOcGMP,PDEcGMP原发性肺动脉高压Wilkens.Circulation.2001;
104:
1218Abrams.Heart.2000;
84:
E4Jackdson.IntJClinPract.2002;
56:
397Michelakis.Circulation.2002;
105:
2398Ghofrani.AnnInternMed.2002;
136:
5155型磷酸二酯酶抑制剂其他5型磷酸二酯酶抑制剂他达那非(Tadalafil),25mg艾地那非(Vardenafil),20mg未来展望:
一氧化氮合酶(nitricoxidesynthaseNOS)基因转移expressionofendothelialNO-synthase(eNOS)isreducedinlungsofpatientswithPHTGiaid,NEnglJMed1995;
333:
214adenoviral-mediatedlNOSgenetransfertorateNOStransfer:
increaseeNOSexpression,reduceacutehypoxicpulmonaryvasoconstriction(HPV)invivoJanssensJClinInvest.1996;
98:
317iNOStransfer:
increaseexhaledNOlevel,reducechronichypoxicpulmonaryhypertensionandpulmonaryvascularremodelinginvivoBudts.Circulation.2000;
102:
2880eNOSandiNOStransfer:
decreasetheefficacyofvasoconstrictors,increasetheefficacyofendothelium-dependentvasodilatorinisolatedpulmonaryarteriesJiang.AmJRespirCritCareMed.2000;
161:
A461前列环素合酶(prostacyclinsynthasePGIS)基因转移prostacyclinsynthase(PGIS)locatedintheendotheliumandSMCofarteiries,epithelialdecreasedPGISexpressioninvesselsofPHTpatientssTuder.AmJRespirCritCareMed.1999;
159:
1925PGIStransgenicmiceincreasedPGI2levellowerRVSP,novesselwallhypertrophytochronichypoxiaGeraci.JClinInvest.1999;
103:
1509PAH,ClassIII/IVConventionaltherapy(C)(oralanticoagu